SurgiQuest sued Lexion last year, alleging infringement of patent no. 9,095,372B2, covering a “system and method for improved gas recirculation in surgical trocars with pneumatic sealing,” by Lexion’s line of Insuflow Synergy Port devices.
Lexion asked the U.S. Patent Trial & Appeals Board for an inter partes review of the patent, arguing that the first 11 claims are unpatentable for obviousness.
The PTAB agreed, ruling June 29 that a person of ordinary skill in the art would have found the claims to be obvious.
Utica, N.Y.-based Conmed paid $265 million for SurgiQuest back in January 2016, inheriting its various beefs with Lexion. In April 2017, SurgiQuest lost a $12.2 million false advertising case against its rival when a jury in the U.S. District Court for Delaware found it liable for $2.2 million in compensatory damages and an additional $10 million in punitive damages for false advertising in marketing literature for its AirSeal system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.